Quarterly ResultMay 7, 2026, 04:32 PM
IN8bio GBM Data Shows ~97% PFS Improvement; Q1 Net Loss $5.1M
AI Summary
IN8bio reported Q1 2026 financial results and significant clinical and preclinical advancements. The company's DeltEx drug resistant immunotherapy for newly diagnosed glioblastoma (GBM) demonstrated a 97% improvement in median progression-free survival (mPFS) compared to standard-of-care, with median overall survival (mOS) currently at 17.2+ months. Additionally, IN8bio is advancing its next-generation γδ T cell engager platform (INB-619), with preclinical data showing complete B cell depletion and minimal cytokine release. The company will host an R&D Day on May 21, 2026, and expects initial animal data for INB-619 in 2026.
Key Highlights
- IN8bio's GBM program (INB-200/400) showed median progression-free survival (mPFS) of 13.0 months vs. 6.6 months for standard-of-care, a 97% improvement.
- Median overall survival (mOS) in repeat dose GBM patients is 17.2+ months, surpassing 13.2 months for the SOC control arm.
- Preclinical data for INB-619, a CD19-targeting γδ T cell engager, showed complete B cell depletion and minimal cytokine release syndrome (CRS).
- The company will host an R&D Day on May 21, 2026, in New York City to provide program updates.
- Cash and cash equivalents were $21.9 million as of March 31, 2026.
- Research and Development (R&D) expenses were $2.6 million for the three months ended March 31, 2026.
- Net loss for Q1 2026 was $5.1 million, or $0.26 per basic and diluted common share.